Combined analysis of phase III trials evaluating [99mTc] tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma

Vernon K. Sondak*, Dennis W. King, Jonathan S. Zager, Schlomo Schneebaum, Julian Kim, Stanley P.L. Leong, Mark B. Faries, Bruce J. Averbook, Steve R. Martinez, Christopher A. Puleo, Jane L. Messina, Lori Christman, Anne M. Wallace

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

117 Scopus citations

Fingerprint

Dive into the research topics of 'Combined analysis of phase III trials evaluating [99mTc] tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science